ArticleGMS infectious diseases2017
Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany.
Article in GMS infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Worldwide literature on epidemiology of human alveolar echinococcosis: a systematic review of research published in the twenty-first century.Infection · 2019Pooled it
- Correlation between imaging features and rEm18 antibodies in alveolar echinococcosis: results from a multicenter study in France.Parasite (Paris, France) · 2025Trial
- HLA profiles and susceptibility to Alveolar echinococcosis: evidence from a large cohort with population and household controls.Emerging microbes & infections · 2026Article
- Screening for alveolar echinococcosis in household members of affected patients: A cross-sectional study with a pooled comparison to endemic population screenings.One health (Amsterdam, Netherlands) · 2026Article
- Postoperative CT-derived spleen volumetry for recurrence risk stratification after curative-intent surgery for hepatic alveolar echinococcosis.Infection · 2026Article
- Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model.PLoS neglected tropical diseases · 2026Article
- Hexokinase-3 upregulation and histone H3K18 lactylation mediate murine liver fibrosis induced by Echinococcus multilocularis.PLoS neglected tropical diseases · 2026Article
- Increasing Case Numbers and Earlier Age at Diagnosis of Alveolar Echinococcosis: Insights from a 13-Year Retrospective Swiss Study.Pathogens (Basel, Switzerland) · 2026Observational
- A Multicenter Retrospective Study of Cystic and Alveolar Echinococcosis Patients in the United States (1997-2024).The American journal of tropical medicine and hygiene · 2026Observational
- In vitro screening of the open-access Pandemic Response Box reveals ESI-09 as a compound with activity against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2025Article
- Clinical, Diagnostical, and Epidemiological Findings at First Diagnosis of Alveolar Echinococcosis: A Single-Center Cohort Study.Visceral medicine · 2025Article
- Two Decades of Living with Echinococcus multilocularis: A Clinical Epidemiology Study on Human Alveolar Echinococcosis in Hungary.Infectious diseases and therapy · 2025Article
- Unexplained subcutaneous swelling: Keep echinococcosis in mind! Report of two primary extrahepatic subcutaneous echinococcosis cases and literature review.PLoS neglected tropical diseases · 2025Review
- Epidemiological and clinical characteristics of patients in the alveolar echinococcosis registry, France, 1982 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Comprehensive Survival Analysis of Alveolar Echinococcosis Patients, University Hospital Zurich, Zurich, Switzerland, 1973-2022.Emerging infectious diseases · 2025Article
- Host Proteins inInternational journal of molecular sciences · 2025Article
- Human Alveolar Echinococcosis-A Neglected Zoonotic Disease Requiring Urgent Attention.International journal of molecular sciences · 2025Review
- Efficacy and mechanism of action of harmine derivative H-2-104 against Echinococcus granulosus infection in mice.BMC veterinary research · 2025Article
- [Hepatotoxicity due to albendazole: safe alternatives for echinococcosis therapy].Innere Medizin (Heidelberg, Germany) · 2025Article
- Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond.Parasitology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alveolar echinococcosis (AE) is the most Iethal human helminthic infection. The malignancy-like disease is rare, but morbidity and treatment costs are high. Objective of the study was to identify factors at baseline and during specific AE therapy influencing the long-term outcome of the disease. All patients with AE seen at the specialized treatment unit in Ulm between January 1992 and December 2011 were included in the analysis. The data of 312 patients were analyzed; 108 were diagnosed before 2000 (series A), 204 since 2000 (series B); 290 received specific AE treatment. Patients of series B were more often symptom-free at diagnosis (44.1% vs. 21.3%), had lower disease stages (50.0% vs. 34.2%) and more complete resections (57.7% vs. 20.0%), but higher rates of side effects and drug toxicity (54.1% vs. 40.8%). In series B, more patients remained relapse- or progression-free after 5 years (90.5% vs. 82.8%); after 10 years, the ratio of relapses converged (70.3% vs. 66.9%, p=0.0507). Relapses or progression occurred more often after incomplete surgery or long treatment pauses. The 5-year and 10-year survival rates were 96.9% and 90.6%, respectively, and 17% of the patients were cured. We observed a shift towards early diagnosis, earlier initiation of specific therapy and more complete resections after 2000. Although diagnosis and treatment of AE pose a challenge, with an individual interdisciplinary management 88.8% of the patients have a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.